CHEK2 and breast carcinoma: Three of these patients carried constitutional known or expected pathogenic variants in genes from the ACMG Secondary Findings minimum list (MLH1, MUTYH, RET) [12] and one carried compound-heterozygous VUS in MYH7. One further patient had a pathogenic variant in SDHA, associated with hereditary paraganglioma syndrome (OMIM *600857) and two patients had pathogenic and likely pathogenic mutations in CHEK2, which is associated with prostate and breast cancer susceptibility (OMIM +604373).